LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,416,083
تعداد دریافت فایل اصل مقاله11,291,752
Pourmohamadi, Nasir, Pour Abdollah Toutkaboni, Mihan, Hayati Roodbari, Nasim, Tabarsi, Payam, Baniasad, Shadi. (1402). Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study. سامانه مدیریت نشریات علمی, 48(5), 474-483. doi: 10.30476/ijms.2023.96145.2765
Nasir Pourmohamadi; Mihan Pour Abdollah Toutkaboni; Nasim Hayati Roodbari; Payam Tabarsi; Shadi Baniasad. "Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study". سامانه مدیریت نشریات علمی, 48, 5, 1402, 474-483. doi: 10.30476/ijms.2023.96145.2765
Pourmohamadi, Nasir, Pour Abdollah Toutkaboni, Mihan, Hayati Roodbari, Nasim, Tabarsi, Payam, Baniasad, Shadi. (1402). 'Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study', سامانه مدیریت نشریات علمی, 48(5), pp. 474-483. doi: 10.30476/ijms.2023.96145.2765
Pourmohamadi, Nasir, Pour Abdollah Toutkaboni, Mihan, Hayati Roodbari, Nasim, Tabarsi, Payam, Baniasad, Shadi. Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study. سامانه مدیریت نشریات علمی, 1402; 48(5): 474-483. doi: 10.30476/ijms.2023.96145.2765

Association of Cytochrome P450 2E1 and N-Acetyltransferase 2 Genotypes with Serum Isoniazid Level and Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Cross-Sectional Study

Iranian Journal of Medical Sciences
مقاله 5، دوره 48، شماره 5، آذر 2023، صفحه 474-483    اصل مقاله (520.45 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2023.96145.2765
نویسندگان
Nasir Pourmohamadi1؛ Mihan Pour Abdollah Toutkaboni2؛ Nasim Hayati Roodbari1؛ Payam Tabarsi3؛ Shadi Baniasad* 4
1Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
2Molecular Medicine Laboratory, Department of Pathology, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Clinical Tuberculosis and Epidemiology Research Center, National Research Institute for Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
چکیده
Background: Anti-tuberculosis drug-induced hepatotoxicity can result from genetic polymorphism of the isoniazid (INH) metabolizing enzyme. This study aimed to determine the effect of genetic polymorphism of N-acetyltransferase 2 (NAT2) and cytochrome P450 2E1 (CYP2E1) genes on serum isoniazid level and drug-induced hepatotoxicity. 
Methods: A cross-sectional study was conducted on 120 patients (with and without hepatotoxicity) with pulmonary tuberculosis from June 2019 to April 2022 in Tehran (Iran). High-performance liquid chromatography was used to measure the serum concentration of INH and acetylisoniazid (AcINH). NAT2 and CYP2E1 genotypes were determined using polymerase chain reaction and restriction fragment length polymorphism methods. Data were analyzed using SPSS software (version 22.0) with independent two-sample t test, Chi square test, or Fisher’s exact test. P<0.05 was considered statistically significant.
Results: A total of 40 patients showed hepatotoxicity. The risk of anti-tuberculosis drug-induced hepatotoxicity was significantly higher in patients who are slow acetylator (SA) phenotype than in rapid or intermediate acetylator (P<0.001). NAT2*4/*4 genotypes were not found in patients with hepatotoxicity. The frequency of NAT2*5 and NAT2*6 haplotypes and serum INH concentration was significantly higher in patients with hepatotoxicity than in those without (P=0.003, P<0.001, and P<0.001, respectively). NAT2*4 haplotype was correlated with protection against hepatotoxicity. A combination of SA and CYP2E1 C1/C1 genotype was significantly associated with hepatotoxicity (P<0.001). 
Conclusion: Hepatotoxicity in Iranian patients with tuberculosis was confirmed due to the presence of NAT2 SA polymorphism. Determining NAT2 and CYP2E1 genotypes and/or INH concentration can be a valuable tool to identify patients susceptible to hepatotoxicity.

تازه های تحقیق

Nasir Pourmohamadi (Google Scholar)

Shadi Baniasadi (Google Scholar)

کلیدواژه‌ها
Hepatotoxicity؛ Isoniazid؛ Polymorphism؛ NAT2؛ CYP2E1
سایر فایل های مرتبط با مقاله
مراجع
  1. Udomsinprasert W, Chanhom N, Suvichapanich S, Wattanapokayakit S, Mahasirimongkol S, Chantratita W, et al. Leukocyte telomere length as a diagnostic biomarker for anti-tuberculosis drug-induced liver injury. Sci Rep. 2020;10:5628. doi: 10.1038/s41598-020-62635-2. PubMed PMID: 32221362; PubMed Central PMCID: PMCPMC7101399.
  2. Jaramillo-Valverde L, Levano KS, Tarazona DD, Capristano S, Zegarra-Chaponan R, Sanchez C, et al. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients. Mol Genet Genomic Med. 2022;10:e1987. doi: 10.1002/mgg3.1987. PubMed PMID: 35751408; PubMed Central PMCID: PMCPMC9356556.
  3. Grace AG, Mittal A, Jain S, Tripathy JP, Satyanarayana S, Tharyan P, et al. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;12:CD012918. doi: 10.1002/14651858.CD012918.pub2. PubMed PMID: 31828771; PubMed Central PMCID: PMCPMC6953336.
  4. Tao G, Huang J, Moorthy B, Wang C, Hu M, Gao S, et al. Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. Expert Opin Drug Metab Toxicol. 2020;16:1109-24. doi: 10.1080/17425255.2020.1815705. PubMed PMID: 32841068; PubMed Central PMCID: PMCPMC8059872.
  5. Pillaye JN, Marakalala MJ, Khumalo N, Spearman W, Ndlovu H. Mechanistic insights into antiretroviral drug-induced liver injury. Pharmacol Res Perspect. 2020;8:e00598. doi: 10.1002/prp2.598. PubMed PMID: 32643320; PubMed Central PMCID: PMCPMC7344109.
  6. Bakayev VV, Mohammadi F, Bahadori M, Sheikholslami M, Javeri A, Masjedi MR, et al. Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals. Eur J Clin Pharmacol. 2004;60:467-71. doi: 10.1007/s00228-004-0799-z. PubMed PMID: 15316701.
  7. Torkaman-Boutorabi A, Hoormand M, Naghdi N, Bakhshayesh M, Milanian I. Genotype and allele frequencies of N-acetyltransferase 2 and glutathione S-transferase in the Iranian population. Clin Exp Pharmacol Physiol. 2007;34:1207-11. doi: 10.1111/j.1440-1681.2007.04753.x. PubMed PMID: 17880378.
  8. Teixeira RL, Morato RG, Cabello PH, Muniz LM, Moreira Ada S, Kritski AL, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz. 2011;106:716-24. doi: 10.1590/s0074-02762011000600011. PubMed PMID: 22012226.
  9. Fukino K, Sasaki Y, Hirai S, Nakamura T, Hashimoto M, Yamagishi F, et al. Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci. 2008;33:187-95. doi: 10.2131/jts.33.187. PubMed PMID: 18544910.
  10. Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In Vivo. 2011;25:803-12. PubMed PMID: 21753138.
  11. Erwin ER, Addison AP, John SF, Olaleye OA, Rosell RC. Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. Tuberculosis (Edinb). 2019;116S:S66-S70. doi: 10.1016/j.tube.2019.04.012. PubMed PMID: 31076322.
  12. Khan S, Mandal RK, Elasbali AM, Dar SA, Jawed A, Wahid M, et al. Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence. Biosci Rep. 2019;39. doi: 10.1042/BSR20180845. PubMed PMID: 30509962; PubMed Central PMCID: PMCPMC6331676.
  13. Satyaraddi A, Velpandian T, Sharma SK, Vishnubhatla S, Sharma A, Sirohiwal A, et al. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. Int J Tuberc Lung Dis. 2014;18:188-95. doi: 10.5588/ijtld.13.0128. PubMed PMID: 24429311.
  14. Jeong I, Park JS, Cho YJ, Yoon HI, Song J, Lee CT, et al. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. J Korean Med Sci. 2015;30:167-72. doi: 10.3346/jkms.2015.30.2.167. PubMed PMID: 25653488; PubMed Central PMCID: PMCPMC4310943.
  15. Wang T, Du H, Ma J, Shen L, Wei M, Zhao X, et al. Functional characterization of the chlorzoxazone 6-hydroxylation activity of human cytochrome P450 2E1 allelic variants in Han Chinese. PeerJ. 2020;8:e9628. doi: 10.7717/peerj.9628. PubMed PMID: 32821545; PubMed Central PMCID: PMCPMC7397980.
  16. Richardson M, Kirkham J, Dwan K, Sloan DJ, Davies G, Jorgensen AL. CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis. Syst Rev. 2018;7:204. doi: 10.1186/s13643-018-0861-z. PubMed PMID: 30458875; PubMed Central PMCID: PMCPMC6247669.
  17. AK HK, Sudha V, Ramachandran G. Simple and rapid method for simultaneous determination of isoniazid and acetyl isoniazid in urine by HPLC. Asian Journal of Biomedical and Pharmaceutical Sciences. 2014;4:46-50. doi: 10.15272/ajbps.v4i34.511.
  18. Cai Y, Yi J, Zhou C, Shen X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS One. 2012;7:e47769. doi: 10.1371/journal.pone.0047769. PubMed PMID: 23082213; PubMed Central PMCID: PMCPMC3474796.
  19. Ben Fredj N, Gam R, Kerkni E, Chaabane A, Chadly Z, Boughattas N, et al. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients. Pharmacogenomics J. 2017;17:372-7. doi: 10.1038/tpj.2016.26. PubMed PMID: 27089936.
  20. Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol. 2006;62:423-9. doi: 10.1007/s00228-006-0111-5. PubMed PMID: 16770646.
  21. Cho HJ, Koh WJ, Ryu YJ, Ki CS, Nam MH, Kim JW, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb). 2007;87:551-6. doi: 10.1016/j.tube.2007.05.012. PubMed PMID: 17950035.
  22. Lei S, Gu R, Ma X. Clinical perspectives of isoniazid-induced liver injury. Liver Research. 2021;5:45-52. doi: 10.1016/j.livres.2021.02.001.
  23. Wang T, Yu HT, Wang W, Pan YY, He LX, Wang ZY. Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients. J Int Med Res. 2010;38:977-86. doi: 10.1177/147323001003800324. PubMed PMID: 20819434.
  24. Gupta VH, Amarapurkar DN, Singh M, Sasi P, Joshi JM, Baijal R, et al. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol. 2013;28:1368-74. doi: 10.1111/jgh.12194. PubMed PMID: 23875638.
  25. Seifart HI, Parkin DP, Botha FJ, Donald PR, Van Der Walt BJ. Population screening for isoniazid acetylator phenotype. Pharmacoepidemiol Drug Saf. 2001;10:127-34. doi: 10.1002/pds.570. PubMed PMID: 11499851.
  26. Anitha A, Banerjee M. Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India. Int J Mol Med. 2003;11:125-31. PubMed PMID: 12469231.
  27. Roy B, Ghosh SK, Sutradhar D, Sikdar N, Mazumder S, Barman S. Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients. J Gastroenterol Hepatol. 2006;21:784-6. doi: 10.1111/j.1440-1746.2006.04197.x. PubMed PMID: 16677176.
  28. Olson WA, Dayton PG, Israili ZH, Pruitt AW. Spectrophotofluorometric assay for isoniazid and acetyl isoniazid in plasma adapted to pediatric studies. Clin Chem. 1977;23:745-8. PubMed PMID: 844172.
  29. Milán-Segovia R, Pérez-Flores G, Torres-Tirado J, Hermosillo-Ramírez X, Vigna-Pérez M, Romano-Moreno S. Simultaneous HPLC determination of isoniazid and acetylisoniazid in plasma. Acta Chromatographica. 2007;19:110-8.
  30. Devarbhavi H, Aithal G, Treeprasertsuk S, Takikawa H, Mao Y, Shasthry SM, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int. 2021;15:258-82. doi: 10.1007/s12072-021-10144-3. PubMed PMID: 33641080.
  31. Mohamed Noor NF, Salleh MZ, Mohd Zim MA, Bakar ZA, Fakhruzzaman Noorizhab MN, Zakaria NI, et al. NAT2 polymorphism and clinical factors that increase antituberculosis drug-induced hepatotoxicity. Pharmacogenomics. 2022;23:531-41. doi: 10.2217/pgs-2022-0022. PubMed PMID: 35615896.
  32. Sanni S, Sina H, Baba-Moussa L. Genetic Polymorphisms and Toxicities of First-Line Antituberculosis Drugs: Systematic Review of the Literature. Journal of Tuberculosis Research. 2022;10:124-45. doi: 10.4236/jtr.2022.103010.
  33. El-Jaick KB, Ribeiro-Alves M, Soares MVG, Araujo GEF, Pereira GRC, Rolla VC, et al. Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs. Mem Inst Oswaldo Cruz. 2022;117:e210328. doi: 10.1590/0074-02760210328. PubMed PMID: 35588539; PubMed Central PMCID: PMCPMC9049236.
  34. An HR, Wu XQ, Wang ZY, Zhang JX, Liang Y. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol. 2012;39:535-43. doi: 10.1111/j.1440-1681.2012.05713.x. PubMed PMID: 22506592.
  35. Motta I, Calcagno A, Bonora S. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? Expert Opin Drug Metab Toxicol. 2018;14:59-82. doi: 10.1080/17425255.2018.1416093. PubMed PMID: 29226732.
  36. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology. 2003;37:924-30. doi: 10.1053/jhep.2003.50144. PubMed PMID: 12668988.
  37. Li J, Chen B, Xi WQ, Jia W, Zhang WX, Bian XL. Drug-Drug Interactions and Disease Status Are Associated With Irinotecan-Induced Hepatotoxicity: A Cross-Sectional Study in Shanghai. J Clin Pharmacol. 2022;62:1160-9. doi: 10.1002/jcph.2059. PubMed PMID: 35396702.
آمار
تعداد مشاهده مقاله: 818
تعداد دریافت فایل اصل مقاله: 639


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب